EcoDrugPlus

Prostaglandin E Receptor 2a (Subtype Ep2)

Ensembl ID : ENSOJAG00000020069
Gene Symbol: PTGER2A
1 Cross references
202 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSOJAG00000008950
Gene Symbol: PTGER3
1 Cross references
194 Possible Orthologues:

Prostaglandin E Receptor 4 (Subtype Ep4) A

Ensembl ID : ENSOJAG00000017480
Gene Symbol: PTGER4A
1 Cross references
202 Possible Orthologues:

Prostaglandin E Receptor 4 (Subtype Ep4) B

Ensembl ID : ENSOJAG00000010018
Gene Symbol: PTGER4B
1 Cross references
201 Possible Orthologues:

Prostaglandin F Receptor (Fp)

Ensembl ID : ENSOJAG00000007004
Gene Symbol: PTGFR
1 Cross references
195 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSOJAG00000002721
Gene Symbol: PTGIR
1 Cross references
187 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSOJAG00000017650
Gene Symbol: PTGS1
1 Cross references
182 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSOJAG00000002196
Gene Symbol: PTGS1
1 Cross references
212 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 2b

Ensembl ID : ENSOJAG00000000391
Gene Symbol: PTGS2B
1 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Alpha 1

Ensembl ID : ENSOJAG00000011853
Gene Symbol: PSMA1
1 Cross references
270 Possible Orthologues:

Proteasome 20s Subunit Alpha 2a

Ensembl ID : ENSOJAG00000004953
Gene Symbol: PSMA2A
1 Cross references
269 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSOJAG00000017765
Gene Symbol: PSMA3
1 Cross references
239 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).